These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27428571)

  • 21. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
    Echizen H
    Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ilaprazole for the treatment of gastro-esophageal reflux.
    Savarino E; Ottonello A; Martinucci I; Dulbecco P; Savarino V
    Expert Opin Pharmacother; 2016 Oct; 17(15):2107-13. PubMed ID: 27598861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
    Yang S; Deng W; Xie Z; Chen J
    Medicine (Baltimore); 2022 Nov; 101(47):e31807. PubMed ID: 36451489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological characteristics and clinical efficacies of a novel potassium-competitive acid blocker, vonoprazan fumarate].
    Matsukawa J; Inatomi N; Nishida H; Tsukimi Y
    Nihon Yakurigaku Zasshi; 2018; 152(3):104-110. PubMed ID: 30185727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acid suppression therapy: where do we go from here?
    Scarpignato C; Pelosini I; Di Mario F
    Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.
    Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ
    Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.
    Wang D; Zhou D; Liu X; Xu Z; Bai T; Hou X
    Trials; 2023 Dec; 24(1):778. PubMed ID: 38041136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Miura Y; Lefor AK; Yamamoto H
    Biomed Rep; 2021 Mar; 14(3):32. PubMed ID: 33585034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
    Inatomi N; Matsukawa J; Sakurai Y; Otake K
    Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.
    Goirand F; Le Ray I; Bardou M
    Expert Opin Drug Metab Toxicol; 2014 Sep; 10(9):1301-11. PubMed ID: 25019289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders.
    Savarino V; Antonioli L; Fornai M; Marabotto E; Demarzo MG; Zingone F; Ghisa M; Barberio B; Zentilin P; Ribolsi M; Savarino E
    Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):401-410. PubMed ID: 34550866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
    Andersson K; Carlsson E
    Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent Acid Suppression with PPIs and P-CABs: What's New?
    Hunt RH; Scarpignato C
    Curr Treat Options Gastroenterol; 2018 Dec; 16(4):570-590. PubMed ID: 30361857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review.
    Domingues G; Chinzon D; Moraes-Filho JPP; Senra JT; Perrotti M; Zaterka S
    Prz Gastroenterol; 2023; 18(1):47-55. PubMed ID: 37007753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans.
    Kong WM; Sun BB; Wang ZJ; Zheng XK; Zhao KJ; Chen Y; Zhang JX; Liu PH; Zhu L; Xu RJ; Li P; Liu L; Liu XD
    Acta Pharmacol Sin; 2020 Jun; 41(6):852-865. PubMed ID: 31969689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease.
    Tabuchi M; Minami H; Akazawa Y; Ashida M; Hara T; Ichinose K; Kitayama M; Hashiguchi K; Matsushima K; Yamaguchi N; Takeshima F; Kondo H; Kawakami A; Nakao K
    Biomed Rep; 2021 Feb; 14(2):25. PubMed ID: 33408859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.